Acquisition of 80.24% Stake in RF Bio for 57B KRW, Entering Medical Aesthetics & Biotech
Invested 57 billion KRW (8.71% of equity) to acquire a controlling 80.24% stake in RF Bio, diversifying into fillers and regenerative medicine.
Acquisition method: Purchase of 910,747 existing shares (20 billion KRW) and participation in a third-party allotment of 3,369,763 new shares (37 billion KRW).
RF Bio reported 2024 revenue of 20.2 billion KRW and a net loss of 0.65 billion KRW, with total assets of 115.1 billion KRW.
Holds a call option on the remaining 489,939 shares held by RF Tech for three years after closing.
Subject to review and approval by the Ministry of Trade, Industry and Energy regarding national core technology, which may affect the acquisition timeline.
The acquisition aims to enter new businesses by securing a medical aesthetics and biotech portfolio, expected to enhance long-term enterprise value.
[AI Summary]Access Bio invested 57 billion KRW (8.71% of equity) to acquire an 80.24% stake in loss-making RF Bio, expanding into medical aesthetics and biotech. This strategic move prioritizes long-term growth over short-term financial burden, with regulatory approval and the target's profitability improvement being key factors for future stock performance.
KOSDAQ Filing Information
Filing: [Correction of Description] Decision on Acquisition of Stocks and Equity Securities of Other Corporations